Aussie firm reveals next-gen MIGS device in pipeline

Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. It is also progressing towards a pivotal US study for its 2RT laser therapy for intermediate AMD that could fulfil a distinct gap in a multi-billion-dollar market. Read more

TGA approves Luxturna gene therapy

In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true gene therapy, indicated for a rare form of inherited retinal disease (IRD). Read more

Clinical model puts dry eye first

In the final instalment of Insight’s five-part dry eye series, optometrist Ms Marilyn Stern reveals how low overheads and no refraction equipment set Perth’s first dedicated dry eye clinic apart. So too does its patient demographic, with several teens counted among them. Read more

Optimel secures its niche

In Part 4 of Insight’s dry eye series, Melcare Biomedical CEO Anthony Moloney reveals how his company’s Australian-made product has proven to significantly reduce the severity of dry eye symptoms when compared with a conventional ocular lubricant – and hints there may be further therapies on the horizon. Read more

Eylea biosimilar embarks on Phase 3 trial

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept). Read more

Dry Eye Directory grabs global attention

In Part 2 of Insight’s dry eye series, independent optometrist Mr Leigh Plowman discusses how Google rankings of a dry eye directory introduced last year have been building worldwide, connecting patients to practices who have invested in treating dry eye. Read more

New approaches targeting dry eye subtypes

In Part 1 of Insight’s dry eye series, Dr Laura Downie explains how an explosion in global investment in dry eye research and development is paving the way for a range of new therapies, particularly those more specifically aimed at dry eye subtypes. Read more

Dry eye treatment in Australia

Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence of dry eye is increasing significantly. This is a complex and multifactorial disease which begs the question: Are we doing enough for our patients and how could we do better? Read more